Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%

Chimeric Therapeutics (ASX:CHM) recruited the first patient for its phase one/two trial for the cell therapy CDH17, according to a Monday filing with the Australian bourse.The trial aims to

MT Newswires50minutes ago

Chimeric Advances Cancer Treatment With First Patient Trial

Chimeric Therapeutics Ltd. (AU:CHM) has released an update.

TipRanks22:07 ET

Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4%

Chimeric Therapeutics (ASX:CHM) said the Phase 1/2 multi-center and first-in-human clinical trial for its CHM CDH17 CAR T cell therapy is now open for enrollment at SCRI Oncology Partners in Nashville

MT NewswiresMay 21 21:56 ET

Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial

Chimeric Therapeutics (ASX:CHM) secured ethics approval for the start of the multi-site Phase 1/2 clinical trial of CHM CDH17 cell therapy in patients with advanced gastrointestinal cancers, according

MT NewswiresMay 19 19:35 ET

Chimeric Therapeutics Reopens Enrollment in Phase 1B Cell Therapy Study

Chimeric Therapeutics (ASX:CHM) said that enrollment in the Phase 1B study of CHM CORE-NK cell therapy plus vactosertib has reopened, according to a Thursday filing with the Australian Securities Exch

MT NewswiresMay 15 20:55 ET

Chimeric Therapeutics Appoints COO; Shares Rise 4%

Chimeric Therapeutics (ASX:CHM) appointed Rebecca McQualter as its chief operating officer, the clinical stage cell therapy company said Thursday. McQualter has previously worked at companies such as

MT NewswiresMay 1 20:37 ET